Compare Stocks: TERN, INCY, BNTX, and MRNA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$92.29 +1.0%	$91.47	$79.52 ▼ $124.00	$23.37B	1.27	1.03 million shs	1.16 million shs
INCY Incyte	$119.80 -0.7%	$110.44	$76.45 ▼ $132.60	$24.31B	0.76	1.79 million shs	1.13 million shs
MRNA Moderna	$56.15 -1.5%	$59.74	$22.28 ▼ $85.60	$22.50B	0.91	8.75 million shs	3.15 million shs
TERN Terns Pharmaceuticals	$52.95	$51.03	$2.65 ▼ $53.19	$6.12B	-0.37	4.84 million shs	6.35 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	-0.98%	-1.19%	-6.35%	-4.10%	-16.98%
INCY Incyte	+1.83%	-7.18%	+3.20%	+20.78%	+54.54%
MRNA Moderna	+3.51%	+2.27%	-28.44%	+16.98%	+106.50%
TERN Terns Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+820.87%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$92.29 +1.0%	$91.47	$79.52 ▼ $124.00	$23.37B	1.27	1.03 million shs	1.16 million shs
INCY Incyte	$119.80 -0.7%	$110.44	$76.45 ▼ $132.60	$24.31B	0.76	1.79 million shs	1.13 million shs
MRNA Moderna	$56.15 -1.5%	$59.74	$22.28 ▼ $85.60	$22.50B	0.91	8.75 million shs	3.15 million shs
TERN Terns Pharmaceuticals	$52.95	$51.03	$2.65 ▼ $53.19	$6.12B	-0.37	4.84 million shs	6.35 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	-0.98%	-1.19%	-6.35%	-4.10%	-16.98%
INCY Incyte	+1.83%	-7.18%	+3.20%	+20.78%	+54.54%
MRNA Moderna	+3.51%	+2.27%	-28.44%	+16.98%	+106.50%
TERN Terns Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+820.87%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.74	Moderate Buy	$129.13	40.71% Upside
INCY Incyte	2.43	Hold	$120.40	-0.90% Downside
MRNA Moderna	1.88	Reduce	$42.13	-26.72% Downside
TERN Terns Pharmaceuticals	2.27	Hold	$55.14	4.13% Upside

Current Analyst Ratings Breakdown

Latest TERN, INCY, BNTX, and MRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/5/2026	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$142.00
8/4/2026	INCY Incyte	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$121.00 ➝ $137.00
8/3/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/3/2026	MRNA Moderna	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/3/2026	INCY Incyte	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$41.00 ➝ $60.00
8/3/2026	INCY Incyte	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$131.00 ➝ $155.00
7/29/2026	INCY Incyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
7/29/2026	INCY Incyte	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$99.00 ➝ $109.00
7/29/2026	INCY Incyte	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$136.00 ➝ $150.00
7/29/2026	INCY Incyte	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$119.00

(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$3.25B	7.15	$1.33 per share	69.10	$96.59 per share	0.95
INCY Incyte	$5.14B	4.79	$6.34 per share	19.16	$31.30 per share	3.88
MRNA Moderna	$1.94B	11.81	N/A	N/A	$16.93 per share	3.40
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$9.70 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$1.29B	-$5.88	N/A	N/A	N/A	-44.39%	-5.30%	-4.62%	N/A
INCY Incyte	$1.29B	$7.85	15.48	15.62	3.80	27.71%	29.93%	22.88%	N/A
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	N/A
TERN Terns Pharmaceuticals	-$96.21M	-$1.03	N/A	N/A	N/A	N/A	-20.02%	-19.37%	N/A

Latest TERN, INCY, BNTX, and MRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million
7/28/2026	Q2 2026	INCY Incyte	$2.15	$3.09	+$0.94	$2.81	$1.50 billion	$1.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	8.80	8.74
INCY Incyte	N/A	4.59	4.51
MRNA Moderna	0.09	2.29	2.18
TERN Terns Pharmaceuticals	N/A	62.41	62.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
INCY Incyte	96.97%
MRNA Moderna	75.33%
TERN Terns Pharmaceuticals	98.26%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
INCY Incyte	16.20%
MRNA Moderna	10.80%
TERN Terns Pharmaceuticals	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
INCY Incyte	2,844	202.70 million	169.86 million	Optionable
MRNA Moderna	4,700	399.24 million	353.93 million	Optionable
TERN Terns Pharmaceuticals	40	115.52 million	113.79 million	Not Optionable

TERN, INCY, BNTX, and MRNA Headlines

Recent News About These Companies

Merck cuts 2026 profit forecast on Terns acquisition charges

August 4 at 9:52 AM | finance.yahoo.com

Terns charge tips Merck into a second-quarter loss as sales rise 5%

August 4 at 9:52 AM | thepharmaletter.comT

How The Merck (MRK) Investment Story Is Shifting With Terns Deal And Oncology Updates

May 18, 2026 | finance.yahoo.com

Merck completes acquisition of Terns Pharmaceuticals

May 6, 2026 | pharmabiz.comP

MSD (Merck) to acquire Terns Pharmaceuticals in USD 6.7 billion deal

May 6, 2026 | pharmiweb.comP

Merck adds to cancer drug portfolio with new acquisition

May 5, 2026 | wfmz.comW

Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

May 5, 2026 | businesswire.com

Merck's Keytruda Surge: A Boost Amid Acquisition Costs

April 30, 2026 | devdiscourse.comD

Merck still sees ‘compelling’ outlook for Terns leukemia drug

April 30, 2026 | finance.yahoo.com

Oppenheimer downgrades Terns Pharmaceuticals (TERN)

April 28, 2026 | msn.com

Terns Pharmaceuticals gets FDA breakthrough status for leukemia drug

April 27, 2026 | investing.com

Terns Pharmaceuticals Gets Breakthrough Designation for Leukemia Treatment

April 27, 2026 | marketwatch.com

Buy, Sell or Hold MRK Stock With Q1 Earnings Around the Corner?

April 27, 2026 | zacks.com

Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia

April 27, 2026 | globenewswire.com

Pharma giants see trial wins, EU approvals, and M&A progress

April 24, 2026 | msn.com

Merck’s $6.7B Terns deal clears antitrust review

April 24, 2026 | msn.com

Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS) and Terns Pharmaceuticals (TERN)

April 21, 2026 | theglobeandmail.com $https://www.theglobeandmail.com/investing/markets/stocks/GUTS/pressreleases/984947/analysts-offer-insights-on-healthcare-companies-fractyl-health-inc-guts-and-terns-pharmaceuticals-tern/$

Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN

April 10, 2026 | businesswire.com

Why Terns Pharmaceuticals Stock Rocked the Market in March

April 8, 2026 | fool.com

Terns rebuffed a higher bid before selling to Merck

April 7, 2026 | biopharmadive.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TERN, INCY, BNTX, and MRNA Company Descriptions

BioNTech NASDAQ:BNTX

$92.29 +0.94 (+1.03%)

As of 03:33 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Incyte NASDAQ:INCY

$119.80 -0.80 (-0.66%)

As of 03:33 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Moderna NASDAQ:MRNA

$56.15 -0.84 (-1.48%)

As of 03:33 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Terns Pharmaceuticals NASDAQ:TERN

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TERN, INCY, BNTX, and MRNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TERN, INCY, BNTX, and MRNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TERN, INCY, BNTX, and MRNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TERN, INCY, BNTX, and MRNA Company Descriptions

BioNTech NASDAQ:BNTX

Incyte NASDAQ:INCY

Moderna NASDAQ:MRNA

Terns Pharmaceuticals NASDAQ:TERN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TERN, INCY, BNTX, and MRNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TERN, INCY, BNTX, and MRNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TERN, INCY, BNTX, and MRNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TERN, INCY, BNTX, and MRNA Company Descriptions

BioNTech NASDAQ:BNTX

Incyte NASDAQ:INCY

Moderna NASDAQ:MRNA

Terns Pharmaceuticals NASDAQ:TERN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools